Brief: NextCell Pharma: Protrans Cell Therapy Maintains Insulin Production Effect 3.5 Years After Treatment
18/10/2022 15:30
Oct 18 (Reuters) - NextCell Pharma AB NXTCL.ST :
* PROTRANS CELL THERAPY MAINTAINS INSULIN PRODUCTION EFFECT
3.5
YEARS AFTER TREATMENT
* INTERIM ANALYSIS CONCLUDES THAT HIGH-DOSE TREATMENT
PROVIDES
HIGHEST AND LONGEST-LASTING THERAPEUTIC EFFECT IN TYPE I
DIABETIC PATIENTS
Source text for Eikon: ID:nWkr21XMDF
Further company coverage: NXTCL.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on NextCell Pharma AB
See all newsBrief: NextCell Pharma Q1 Operating Income At SEK 2.8 Million
Brief: Nextcell Pharma Q4 Operating Income SEK 1.8 Mln
Brief: Nextcell Pharma Says ProTrans Data Show Insulin Production Preservation
Brief: NextCell Board Proposes Directed Issue Of 15,000,000 Shares
Brief: Nextcell Decides To Propose Directed Share Issue Of SEK 15 Mln